Aktienanalyse zu AC Immune AG (ACIU)ACIUAC Immune AG

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology. It operates in the Healthcare sector.

AC Immune SA (ACIU) appears to be a good buy right now due to its recent turnaround in net income, reporting a profit of 2.4 million CHF in Q2 2026, compared to significant losses in previous quarters. Additionally, the stock has a current price of 2.39 CHF, which is below the Fibonacci Pivot level of 2.53 CHF, indicating potential for upward movement. The stock's RSI is at 31.125, suggesting it is oversold and may rebound soon. However, the main risk is the company's high forward P/E ratio of 16.64, indicating that the market expects significant growth, which may not materialize if future earnings disappoint.

3 analysts cover ACIU: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.